PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Hereditary sensory and autonomic neuropathy

Drugs in development · updated 30 October 2026

Hereditary sensory and autonomic neuropathy: drugs in development

As of 30 October 2026 there are 5 active clinical trials (recruiting or ongoing, phases I–III) on 6 drugs for hereditary sensory and autonomic neuropathy. 4 are experimental, that is not yet approved in the United States.

5Active trials
4Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
DLBS1033II–III1NCT07475065
MiransertibII1NCT04980872
AZD2962I1NCT07064122
Elraglusib Oral Tablets9-ING-41I1NCT06896188

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DexmedetomidineIgalmi®, Precedex®II1NCT06148311
RetifanlimabINCMGA00012, Zynyz®I1NCT06896188

Sorted by most advanced phase and number of active trials.

All 6 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009477 “Hereditary Sensory and Autonomic Neuropathies”.

ItalianoFrançaisDeutsch